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Summary
 
Human Fas ligand (L) (CD95L) and tumor necrosis factor (TNF)-
 
a
 
 
 
undergo metalloprotein-
ase-mediated proteolytic processing in their extracellular domains resulting in the release of sol-
uble trimeric ligands (soluble [s]FasL, sTNF-
 
a
 
) which, in the case of sFasL, is thought to be im-
plicated in diseases such as hepatitis and AIDS. Here we show that the processing of sFasL
occurs between Ser126 and Leu127. The apoptotic-inducing capacity of naturally processed
sFasL was reduced by 
 
.
 
1,000-fold compared with membrane-bound FasL, and injection of
high doses of recombinant sFasL in mice did not induce liver failure. However, soluble FasL
retained its capacity to interact with Fas, and restoration of its cytotoxic activity was achieved
both in vitro and in vivo with the addition of cross-linking antibodies. Similarly, the marginal
apoptotic activity of recombinant soluble TNF-related apoptosis-inducing ligand (sTRAIL),
another member of the TNF ligand family, was greatly increased upon cross-linking. These re-
sults indicate that the mere trimerization of the Fas and TRAIL receptors may not be sufficient
to trigger death signals. Thus, the observation that sFasL is less cytotoxic than membrane-
bound FasL may explain why in certain types of cancer, systemic tissue damage is not detected,
even though the levels of circulating sFasL are high.
 
T
 
umor necrosis factor (TNF)-
 
a
 
 is a potent proinflam-
matory and immunomodulatory agent. However, ele-
vated concentrations of circulating TNF-
 
a
 
 
 
seen during
many host responses may be harmful or even fatal to the
organism. Membrane-bound TNF-
 
a
 
 
 
is synthesized as a
type II membrane protein that acts locally through cell-
to-cell contact. Soluble TNF-
 
a
 
 (s)TNF-
 
a
 
1
 
 is released from
the cell surface as the result of metalloproteinase cleavage
(1, 2). Although both cell surface and secreted TNF-
 
a
 
 ap-
pear to be biologically active, it is the sTNF-
 
a
 
 released into
circulation that appears to be primarily responsible for the
deleterious physiological responses such as cachexia and en-
dotoxic shock. 
Fas ligand (L), a member of the TNF family, is also pro-
cessed and shed from the surface of human cells. FasL has
been implicated in one of the major cytolytic pathways of
cytotoxic T cells (3–5), and is a key element in the elimina-
tion of activated T cells during the downregulation of the
immune response in the periphery (6, 7). Moreover, ex-
pression of FasL in nonlymphoid and tumor cells contrib-
utes to the maintenance of immune privilege of tissues by
preventing the infiltration of Fas-sensitive lymphocytes (8–
12). Presently, it is not clear whether the activities de-
scribed for the ligand are primarily due to the cell surface
form of FasL or whether sFasL is likewise implicated. As
seen for TNF-
 
a
 
, naturally processed and recombinant
sFasLs were found to be active, inducing apoptosis in
mouse cells at a concentration of 
 
,
 
10 ng/ml (13–16). Ele-
vated levels (up to 10 ng/ml) of sFasL were found in sera
from patients with large granular lymphocytic leukemias
and natural killer cell lymphomas (17). Since the adminis-
tration of recombinant FasL or agonistic Fas antibodies into
mice leads to liver failure and to rapid death of the animals
(18, 19), it has been proposed that sFasL is implicated in the
pathogenesis of various diseases such as hepatitis or AIDS
(20–22). The possible implication of sFasL in pathological
processes prompted us to investigate the structure and ac-
tivities of naturally processed sFasL in more detail. Here we
report that, in contrast to membrane-bound FasL, the solu-
ble ligand is only poorly active. A model is suggested
 
1
 
Abbreviations used in this paper:
 
 aa, amino acids; DTAF, dichlorotriaz-
inglaminofluorescein; FADD, Fas-associated death domain–containing
protein; Fas/Fc, Fas with human immunoglobulin Fc; h, human; L,
ligand; mu, murine; s, soluble; TRAIL, TNF-related apoptosis-inducing
ligand; TWEAK, TNF-related ligand that weakly induces apoptosis.
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whereby the apoptotic activity of the membrane-bound
ligand is downregulated upon processing and release. This
assures that circulating sFasL does not cause systemic tissue
damage.
 
Materials and Methods
 
Materials. 
 
The anti-Flag M2 monoclonal antibody and the
anti-Flag M2 antibody coupled to agarose were purchased from
Eastman Kodak Co. (Rochester, NY). Protein A–Sepharose and
cyanogen bromide–activated Sepharose were purchased from Phar-
macia (Uppsala, Sweden). Affinity-purified anti-FasL rabbit poly-
clonal antibody (anti-PE62) was obtained as described (23). Bioti-
nylated anti-Fas antibody Jo-2 was purchased from PharMingen
(San Diego, CA), and dichlorotriazinglaminofluorescein (DTAF)-
labeled streptavidin and anti–mouse antibodies were purchased
from Jackson ImmunoResearch (Milan, La Roche, Switzerland).
Cell culture reagents were obtained from Life Sciences (Basel,
Switzerland). Human (h) TNF-related ligand that weakly induces
apoptosis (TWEAK) cDNA (24) and recombinant hIFN-
 
g
 
 were
provided by J. Browning (Biogen, Cambridge, MA), and murine
(mu)TNF-
 
a
 
 cDNA was a gift from C.V. Jongeneel (Institut Suisse
de Recherche Experimentale sur le Cancer, Epalinges, Switzerland).
Soluble human TNF-related apoptosis-inducing ligand (TRAIL)
and the fusion protein between the extracellular domain of hFas
and the Fc portion of hIgG
 
1
 
 were produced as previously described
(25, 26). muFasL-expressing Neuro-2a cells were described ear-
lier (19).
 
Cells. 
 
Murine B lymphoma A20 and A20R cells (11) were
maintained in DMEM containing 5% heat-inactivated FCS. The
human T lymphoblastoma Jurkat cells, colon adenocarcinoma
HT-29 cells, BJAB Burkitt lymphoma, and murine fibrosarcoma
WEHI-164 cells were grown in RPMI supplemented with 10%
FCS. Human embryonic kidney cells 293 were cultured in
DMEM–nutrient mix F12 (1:1) supplemented with 2% FCS.
293T cells were grown in DMEM, 10% FCS. All media con-
tained antibiotics (penicillin and streptomycin at 5 
 
m
 
g/ml each
and neomycin at 10 
 
m
 
g/ml). The IL-2–dependent murine cyto-
toxic T cell line CT6 (27), a gift of P. Vandenabeele (University
of Ghent, Ghent, Belgium), was grown in RPMI supplemented
with 10% FCS, 1 mM sodium pyruvate, 50 
 
m
 
M 2-mercaptoetha-
nol, 10 mM Hepes, and 10% conditioned EL-4 cell supernatant.
 
Vector Construction and Establishment of Cell Lines Expressing
Ligands of the TNF Family. 
 
hFasL was amplified by PCR from
activated peripheral blood lymphocyte cDNA using the follow-
ing oligonucleotides: JT289 5
 
9
 
-CCTCTACAGGACTGAGAA-
GAAG-3
 
9
 
 and JT290 5
 
9
 
-CAACATTCTCGGTGCCTGTAAC-3
 
9
 
.
muFasL was amplified by PCR from mouse testis cDNA with
primers JT277 5
 
9
 
-AAGGCTGTGAGAAGGAAACC-3
 
9
 
 and JT271
5
 
9
 
-AAGGATCCTAGCTGACCTGTTGGACCTTGC-3
 
9
 
. The
PCR products were subcloned into PCR-II TA-cloning vector
and then resubcloned as EcoRI fragments into the PCR-III
mammalian expression vector (Invitrogen, NV Leek, the Nether-
lands). Point mutations in FasL were obtained by two rounds of
PCR using the following oligonucleotide pairs: for L126E, T7/
JT915 5
 
9
 
-GCTTCTCGAGCTCTGATGCTGTGTGCATC-3
 
9
 
and JT914 5
 
9
 
-CAGAGCTCGAGAAGCAAATAGGC-3
 
9
 
/Sp6;
for S127E, T7/JT917 5
 
9
 
-CAGAGCTCGCTGTGTGCATC-
TGG-3
 
9
 
 and JT916 5
 
9
 
-GCACACAGCGAGCTCTGAGGAGA-
AGCAAATAGGC-3
 
9
 
/Sp6; for SL126-127EE, T7/JT963 5
 
9
 
-GCT-
TCTCCTCCTCGCTAGCTGTGTGCATCTGG-3
 
9
 
 and JT962
5
 
9
 
-AGCGAGGAGGAGAAGCAAATAGG-3
 
9
 
/Sp6.
The extracellular domains of hTWEAK (amino acids [aa]
141–284), muTNF-
 
a
 
 (aa 76–235), and hTNF-
 
a
 
 (aa 85–233)
were amplified by PCR using the oligonucleotide pairs JT560
5
 
9
 
-CTGCAGAAGGAGTGGCGATCGCAGCCCATTATG-3
 
9
 
/
JT561 5
 
9
 
-TCTAGATCAGTGAACCTGGAA-3
 
9
 
, JT408 5
 
9
 
-CCT-
GCAGACCCTCACACTC-3
 
9
 
/JT409 5
 
9
 
-CTCGAGTCACAGA-
GCAAGGAC-3
 
9
 
, and JT437 5
 
9
 
-TCTGCAGAGTGACAAGC-
CTGTAG-3
 
9
 
/JT423 5
 
9
 
-ACTAGTTCACAGGGCAATGAT-3
 
9
 
,
respectively, followed by subcloning into the PCR-II vector.
muTNF-
 
a
 
 and TWEAK were subcloned into a modified version
of the PCR-III vector (26) in frame with the hemagglutinin sig-
nal peptide and Flag epitope, using the PstI site and the suitable 3
 
9
 
restriction site. muTNF-
 
a
 
 and hTNF-
 
a
 
 
 
were subcloned into a
modified pQE9 bacterial expression vector (Qiagen, Basel, Swit-
zerland) containing the Flag sequence between the BamHI and
PstI sites, using the PstI site and the suitable 3
 
9
 
 restriction site.
The vector for Flag tagged, soluble secreted hFasL (residues 103–
281) was prepared as previously described (26). Stably transfected
293 cells were obtained by selection in 800 
 
m
 
g/ml G418 (60%
active) for 2 wk and then cloned. Supernatants of stably trans-
fected clones were harvested after 10–12 d in culture and screened
by Western blotting for expression levels of the protein of inter-
est. For the production of recombinant proteins, selected clones
were grown for 14 d in DMEM–nutrient mix F12 (1:1) (Life
Technologies, Basel, Switzerland) supplemented with 2% FCS, af-
ter which time conditioned supernatants were collected.
 
Purification of Recombinant Proteins. 
 
Flag tagged recombinant
proteins were purified on M2-agarose and eluted in 50 mM citrate-
NaOH, pH 2.5, followed by neutralization with 0.2 volumes of 1 M
Tris-HCl, pH 8. The buffer was exchanged to PBS in concentra-
tors (Centrikon-30; Amicon Corp., Easton, TX). Soluble hFasL
released from cells transfected with full-length FasL was subjected
to phase separation in Triton X-114 (28) and the aqueous phase
was then purified using human Fas with human immunoglobulin
Fc (hFas/Fc)–Sepharose. hFas/Fc–Sepharose was prepared by cou-
pling 4 mg of Fas/Fc to 1 ml cyanogen bromide–activated
Sepharose according to the manufacturer’s instructions. Bound
FasL was eluted as described above for M2-agarose. The concen-
tration of purified proteins was determined by the bicinchoninic
acid method (Pierce Chemical Co., Rockford, IL) using bovine se-
rum albumin as standard, and the purity of the samples was assessed
by SDS-PAGE and Coomassie blue staining. The concentration of
FasL in Neuro-2a cells supernatants was estimated by Western blot-
ting with anti-FasL antibodies using known amounts of recombi-
nant sFasL as standard.
 
Protein Sequencing. 
 
Purified soluble FasL was blotted onto
polyvinylidene difluoride membrane (BioRad Labs., Hercules,
CA) as previously described (29), and then sequenced using a gas
phase sequencer (ABI 120A; Perkin Elmer, Foster City, CA)
coupled to an analyzer (ABI 120A; Perkin Elmer) equipped with
a phenylthiohydantoin C18 2.1 
 
3 
 
250 mm column. Data was an-
alyzed using software (ABI 610; Perkin Elmer).
 
Triton X-114 Extraction of Cells and Phase Separation. 
 
293T cells
transiently transfected with full-length hFasL (wild type and mu-
tants), muFasL, or empty plasmid were transferred in Opti-MEM
medium for 5 d. Supernatants were harvested, and the cells were
lysed in 2% precondensed Triton X-114 in PBS (28) containing a
protease inhibitor cocktail (Cømplete
 
Ô
 
; Boehringer Mannheim
GmbH, Mannheim, Germany) and subjected to phase separation.
Proteins were recovered free of detergent by precipitation with
1.25 volume CHCl3/MeOH (1:4, vol/vol) before Western blot-
ting analysis.
 
Western Blotting. 
 
FasL blotted onto nitrocellulose membranes
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was detected with anti-PE62 (2 
 
m
 
g/ml, in blocking buffer: PBS,
0.5% Tween 20, and 4% skimmed milk), followed by goat anti–
rabbit immunoglobulins coupled to horseradish peroxidase. Per-
oxidase activity was detected by enhanced chemiluminescence.
 
Gel Permeation Chromatography. 
 
The supernatant of Neuro-2a
cells expressing FasL was concentrated 5 times, and then 200 
 
m
 
l was
loaded onto a column (Superdex-200 HR10/30; Pharmacia).
Proteins were eluted in PBS at 0.5 ml/min and fractions were an-
alyzed by Western blotting and cytotoxic assays. The column was
calibrated with standard proteins ferritin (440 kD), bovine serum
albumin (67 kD), and ribonuclease A (13.7 kD).
 
Cytotoxic Assay. 
 
The cytotoxic assay was performed essen-
tially as described previously (26). In brief, 50,000 cells were in-
cubated for 16 h in 100 
 
m
 
l medium containing the indicated con-
centrations of ligands in the presence or absence of 1 
 
m
 
g/ml M2
antibody (2 
 
m
 
g/ml for TRAIL). For HT-29 cells, incubation was
carried out for 40 h in the presence of 50 ng/ml of hIFN-
 
g
 
. Cell
viabilities were determined using PMS/MTS (phenazine metho-
sulfate 3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-
2-[4-sulfophenyl]-2H-tetrazolium, inner salt) reagents (Promega
Corp., Madison, WI), and color was allowed to develop as neces-
sary (typically 1–3 h). The absorbance was measured at 490 nm.
Chromium release assay was performed according to standard
protocols.
 
Cell Proliferation Assay. 
 
CT6 cells were grown for 4 d in the
presence of a reduced concentration of EL-4 supernatant (2.5%)
before the proliferation experiment. Cells were incubated in 96-
well plates (40,000 cells/well) for 16 h with the indicated con-
centrations of muTNF-
 
a
 
 or hTNF-
 
a
 
, in the presence or in the
absence of 2 
 
m
 
g/ml of M2 mAb, and in the absence of EL-4 su-
pernatant. Cells were pulsed for an additional 6 h with [
 
3
 
H]thy-
midine (0.5 
 
m
 
Ci/well), exposed to three cycles of freezing and
thawing, and harvested. [
 
3
 
H]thymidine incorporation was moni-
tored by liquid scintillation counting.
 
In Vitro Fas–FasL Binding Assay. 
 
ELISAs were performed as
previously described (26) except that FasL incubation was done in
the presence or in the absence of 1 
 
m
 
g/ml of M2 antibody.
 
FACS
 
Ò
 
 Staining. 
 
Cells expressing Fas (A20, Jurkat) or not
expressing Fas (A20R) were stained in 25 
 
m
 
l FACS
 
Ò
 
 buffer (PBS,
10% FCS, 0.02% NaN
 
3
 
) with 2.5 
 
m
 
g of Flag tagged soluble hFasL
for 20 min at 4
 
8
 
C, followed by anti-Flag M2 (1.5 
 
m
 
g) and DTAF-
labeled anti–mouse antibody. A20 cells were also stained with 1
 
m
 
g biotinylated Jo-2 antibody followed by streptavidin-DTAF.
 
Treatment of Mice with sFasL, sTRAIL, sTNF-
 
a
 
, and 
 
a
 
-Flag M2
Antibody. 
 
Female BALB/c mice (8 wk old) were injected intra-
venously with 12.5 
 
m
 
g sFasL, sTNF-a, or sTRAIL diluted in 200
ml Ringer’s solution. 10 min later, mice were treated intrave-
nously with antibodies (50 mg, anti-Flag M2, or isotype Ab in 200
ml Ringer’s solution). Mice were autopsied 24 h later or immedi-
ately after death. Fragments of tissues were fixed with 4% para-
formaldehyde in PBS, embedded in paraffin, and 4-mm sections
were stained with hematoxylin and eosin. DNA fragmentation in
paraffin sections was visualized by terminal uridyltransferase
nicked ends labeling (TUNEL) reaction according to the manu-
facturer’s instructions (Apop Tag Peroxidase kit; Oncor Appli-
gene, Basel, Switzerland).
Results and Discussion
An uncharacterized metalloproteinase cleaves the 40-kD
membrane-bound FasL to generate the 26–29 kD-soluble
fragment (13, 14, 17). In agreement with these published
results, we found that processed sFasL was detectable in su-
pernatants of 293 cells transiently or stably transfected with
the full-length human FasL (Fig. 1 A) and that this release
was inhibited upon addition of metalloproteinase inhibitors
(data not shown). Murine FasL underwent a similar con-
version to soluble FasL (Fig. 1 B). By gel filtration chroma-
tography, native sFasL of both species had an apparent mo-
lecular size of z70 kD, indicating that the released ligand
had a homotrimeric structure (Fig. 2 B, and data not
shown). Subsequent isolation of sFasL by Fas/Fc affinity
chromatography and NH2-terminal sequence analysis re-
vealed that sFasL begins with Leu127, suggesting that the
cleavage occurs between Ser126 and Leu127 (Fig. 1 C).
Cleavage in TNF-a occurs in the equivalent region be-
tween Ala76 and Val77, and is mediated by at least two
zinc metalloproteases (TNF-a converting enzyme [TACE],
and a disintegrin and metalloprotease 10 [AD10 or
ADAM10]; references 30–32). Interestingly, the processing
activity of TNF-a is only marginally affected by mutations
Ala76Ser and Val77Leu (32), suggesting that the Ser–Leu
site of FasL may also be a substrate of the TNF-a–convert-
ing proteases, in agreement with the observation that inhib-
itors known to block TNF-a conversion also inhibit FasL
release (14, 15, 17). In contrast, mutations of the flanking
amino acids Ala76 and Val77 to acidic residues influences
the processing of TNF-a. We performed similar mutation
experiments with FasL (Fig. 1 D). Mutations at the P1
(Ser126Glu) and P19 (Leu127Glu) sites partially prevented
the release of sFasL, whereas the double mutation
(Ser126Glu, Leu127Glu) resulted in the loss of detectable
sFasL, indicating that the metalloproteinase present in 293
cells uses this cleavage site. While this manuscript was un-
der revision, Tanaka et al. reported on the identification of
the cleavage of FasL transfected into WR19L cells (33).
Their analysis revealed that membrane-bound human FasL
expressed in the WR19L murine T cell line was cleaved
between Lys129 and Gln130, three amino acid residues
downstream of the cleavage site determined in this paper.
Surprisingly, the mutation of their P1 residue Lys130 into
Ala had no effect on the processing of FasL, and FasL resis-
tant to cleavage was only generated after deletions of sev-
eral amino acid residues, which probably affect or even de-
lete the Ser126–Leu127 processing site. This suggests either
that the murine metalloproteinase present in WR19L cells
has a distinct specificity from its human homologue present
in 293 cells, or that the sFasL found in WR19L cell super-
natants has undergone further proteolytic processing by a
trypsin-like protease.
Unexpectedly, the specific activity of sFasL after its puri-
fication and removal of residual membrane-bound FasL by
Triton X-114 extraction was marginal. Human Jurkat T
cells, which are highly sensitive to apoptosis induced by
anti-Fas antibodies (34), remained viable at sFasL concen-
trations exceeding 1 mg/ml (Fig. 1 E). Recombinant sFasL
corresponding in length to the naturally processed form
was equally inactive (Fig. 1, C and E). This low activity
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was surprising in view of several previous reports showing
that recombinant sFasL or supernatants of cells overexpress-
ing FasL were very active. One well-described example is
the highly apoptotic supernatant of Neuro-2a cells trans-
fected with murine FasL (19), which induces apoptosis in
human Jurkat or mouse A20 cells at concentrations as low
as 1 ng/ml (Fig. 2 A). Western blot analysis (Fig. 2 B) re-
vealed that the recombinant FasL detected in these super-
natants was not the processed sFasL, but corresponded to
the membrane-bound, unprocessed form (Fig. 2 B). Ac-
cordingly, the active fractions were eluted in the void vol-
ume (.500 kD) of a gel filtration column (Superdex 200;
Pharmacia) and not at the expected molecular weight of
trimeric sFasL (70 kD), indicating that the high apoptotic
activity was associated with aggregated forms of FasL. It is
likely that Neuro-2a cells express little or no processing
proteases, and that membrane fragments or vesicles con-
taining the membrane-bound FasLs are released into the
supernatant. This conclusion was corroborated by the ob-
servation that after ultracentrifugation (100,000 g for 2 h),
the activity was recovered in the pellet (data not shown).
Moreover, most of the activity present in some batches of
recombinant sFasL was attributable to small quantities of
contaminating aggregates of sFasL (data not shown). 
Since aggregated or membrane-bound FasL was consid-
erably more active than trimeric sFasL, we reasoned that
controlled cross-linking of sFasL, mimicking membrane-
bound FasL (Fig. 3 D), should lead to an increase in activ-
ity. We took advantage of the presence of a Flag tag on the
recombinant sFasL to induce sFasL aggregation. Fig. 3 A
shows that the mere addition of cross-linking anti-FasL an-
tibodies resulted in a .1,000-fold activity increase of re-
Figure 1. Recombinant and naturally processed sFasLs show marginal apoptotic activity on human cells. (A) Processing of membrane-bound FasL to
sFasL. Cellular extracts of a 293 cell clone stably transfected with human FasL cDNA, were separated into Triton X-114–insoluble (Insoluble) and –soluble
(Soluble) fractions. Cell supernatants (Medium) were separated into detergent and aqueous fractions by Triton X-114 phase separation. Samples were ana-
lyzed by Western blotting for the presence of FasL using an antibody specific for the extracellular segment of the ligand. The indicated FasL and sFasL
bands were absent in mock transfected controls (D, and data not shown). The processed sFasL was purified by Fas/Fc affinity chromatography and visual-
ized by Coomassie blue staining (CB). (B) 293 cells were transfected with mouse FasL cDNA. Total, unfractionated cellular extracts and cell supernatants
were analyzed by Western blotting as described for A. (C) Site of proteinase-induced cleavage of FasL. Metalloproteinase(s) present in 293 cells cleave(s)
membrane-bound FasL at the Ser126–Leu127 bond, liberating a soluble form of FasL. The cleavage site of the TNF-a precursor is shown for compari-
son. (D) The effect of cleavage site mutations on FasL processing. Wild-type (WT) FasL as well as FasL mutated at the P1 site (S126E), at the P19 site
(L127E), and at both the P1 and P19 sites (S126E/L127E) were transiently transfected into 293T cells. Insoluble proteins (containing membrane-associ-
ated FasL) and medium (containing processed sFasL) were analyzed by Western blotting as described above. To achieve similar loading of soluble and
cell-associated FasL, the supernatants corresponding to 10 times more cells were loaded on the gel. A nonspecific band at 60 kD indicates equal loading of
the gel. In the control lane, cell extracts of nontransfected 293 cells were analyzed. (E) Activity of naturally processed (open squares) and recombinant
(closed squares) sFasL on Jurkat T cells. 
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Figure 2. (A) Characterization of FasL in supernatants of Neuro-2a cells transfected with muFasL. Crude supernatants were assayed for FasL activity on
mouse A20 B cells and human Jurkat T cells. (B) Gel filtration analysis of FasL. Supernatants were concentrated and loaded onto a column (Superdex 200;
Pharmacia). Fractions were analyzed for FasL by Western blotting in the presence of SDS (inset), for cell death–inducing activity (closed circles), and for
protein (lines). Molecular size markers and the position of sFasL elution are indicated. 
Figure 3. Increase of the specific
apoptotic activity of sFasL and
sTRAIL, but not sTWEAK, and dif-
ferential modulation of sTNF-a ac-
tivity upon cross-linking of the
ligands. (A) Various cell lines (HT29,
human colon carcinoma; Jurkat, hu-
man T cell leukemia; BJAB, human
B cell lymphoma; A20, mouse B cell
lymphoma) were assayed for their
sensitivity to Flag tagged sFasL in the
presence (closed squares) and absence
(open squares) of aggregating anti-Flag
antibodies. The effect of naturally
processed sFasL on A20 cells is also
shown (open circles). (B) The apopto-
sis-inducing effects of the ligands sTRAIL, sTNF-a, and sTWEAK were assayed in the presence (closed squares) and absence (open squares) of aggregating
anti-Flag antibodies. Most cells are insensitive to the cytotoxic activity of these ligands, and the corresponding results were therefore not included. (C)
The proliferative response of CT6 cells to murine (circles) and human (squares) sTNF-a was monitored in the presence (closed symbols) and absence (open
symbols) of aggregating anti-Flag antibodies (M2) (the data shown are means 6 SD, n 5 3). (D) Model of FasL shedding by metalloproteases and oligo-
merization of Flag tagged sFasL by anti-Flag antibodies.
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combinant sFasL on Jurkat cells. Other cell lines tested re-
sponded identically. Human cells that were insensitive to
sFasL up to 1 mg/ml underwent apoptosis at concentrations
as low as 1–10 ng/ml (BJAB B lymphoma cells, human co-
lon carcinoma HT29) with aggregated sFasL. In agreement
with the higher affinity of human sFasL to mouse Fas (26),
we found that mouse cell lines were generally more sensi-
tive to FasL-mediated apoptosis, as exemplified by the A20
B lymphoma cell. A20 cells underwent apoptosis in the ab-
sence of cross-linking antibodies at 100 ng/ml. This (and
the presence of contaminating aggregates) may explain pre-
vious results showing that recombinant sFasL produced in
yeast was active at 1–10 ng/ml concentrations on the mu-
rine W4 cell line (human cells were not tested; reference 17). 
We tested whether other members of the TNF ligand
family known to induce apoptosis also required cross-link-
ing for their activity (Fig. 3 B). Similar to FasL, TRAIL
(35, 36) was active at low concentrations only in the pres-
ence of cross-linking antibodies (Fig. 3 B). No apoptosis
was observed with sTRAIL at concentrations as high as 5
mg/ml. In contrast, cross-linking of sTWEAK (24) did not
increase its activity (Fig. 3 B), suggesting that this ligand
can exert its apoptotic activity in the soluble form. Interest-
ingly, the activity of sTNF-a was differentially influenced
by the presence of cross-linking antibodies depending on
the receptor triggered. To distinguish between TNFR1-
and TNFR2-mediated effects, we took advantage of the
fact that human TNF-a only binds to murine TNFR1, but
not to murine TNFR2 (37). When TNF-a was added to
WEHI164 cells, which are known to undergo apoptosis
upon stimulation of TNFR1, the activity was independent
of the presence of cross-linking antibodies (Fig. 3 B). In
contrast, the proliferative effect of TNF-a on mouse CT6
cells, which is mediated through TNFR2-dependent sig-
naling pathways and is therefore only observed in response
to murine TNF-a, was highly increased in the presence of
cross-linking antibodies (Fig. 3 C). This is in line with re-
sults demonstrating that membrane-bound TNF-a is the
prime activating ligand for TNFR2-mediated responses
(38).
These results suggested that sFasL and sTRAIL should be
either not or only poorly active in vivo. Indeed, mice in-
jected with 12.5 mg of sFasL or sTRAIL survived and
showed no signs of sickness (Fig. 4 A). In contrast, injec-
tion of sFasL followed by cross-linking anti-Flag antibodies
was fatal and mice died within 3 h, similar to mice treated
with agonistic anti-Fas antibodies (18) or with FasL con-
tained in supernatants of transfected Neuro-2a cells (19).
The cross-linked FasL induced lethal liver hemorrhages and
hepatocyte apoptosis (Fig. 4 B), whereas in the absence of
the anti-Flag antibody, hepatocytes had a normal morphol-
ogy (Fig. 4 B). The administration of the anti-Flag anti-
body alone, or of sFasL with an isotype-matched irrelevant
antibody, also had no effect. Interestingly, treatment of
mice with cross-linked sTRAIL was not lethal, despite the
broad expression of the two cytotoxic TRAIL receptors
(39–42). Whether this is due to the expression of the inhib-
itory TRAILR3 (39, 43, 44), TRAILR4 (45), or other in-
hibitory molecules remains to be determined.
There are two possibilities to explain the absence of apop-
totic activity of sFasL. Either trimeric sFasL displays a low
affinity for its receptor Fas, which is increased upon aggre-
gation and multimeric binding as seen for many protein–
protein interactions involving multivalent partners (46), or
trimerization of Fas is not sufficient to transmit FasL-medi-
ated death signal (in contrast to TWEAK receptor and
TNFR1). We measured sFasL binding to Fas fused to the
human constant region of human IgG (Fas/Fc) in the pres-
ence or in the absence of aggregating antibody (Fig. 5 A),
and to cells (Fig. 5 B). Binding of trimeric sFasL was ob-
served in both cases, and aggregation of sFasL did not sig-
nificantly increase binding efficiency to Fas/Fc.
Most of the members of the TNF ligand family are ini-
tially membrane bound, but can undergo processing and
shedding by metalloendoproteinases. The efficacy of the
ligand release varies. Membrane-bound TNF-a is immedi-
Figure 4. sFasL is not active in
vivo. (A) BALB/c mice (female,
8 wk old) were injected intrave-
nously with sFasL or sTRAIL
(12.5 mg). Within 10 min, anti-
Flag antibodies (50 mg) or control
IgG1 (Ctrl) antibodies (50 mg)
were injected using the same
route of administration. Mice re-
ceiving sFasL and anti-Flag anti-
bodies (four mice) died within 3 h
(mean survival: 2.25 6 0.5 h).
Injection of sFasL alone (four
mice), sFasL followed by control
IgG1 (two mice), anti-Flag alone
(two mice), sTRAIL alone (four
mice), or sTRAIL plus anti-Flag
antibody (four mice) did not lead
to death or to any sign of sickness of the animals. (B) Hepatic injury of mice treated with sFasL in the presence of anti-Flag antibodies or of a murine con-
trol antibody (IgG1). 24 h later (sFasL 1 control antibodies) or immediately after death (sFasL 1 anti-Flag antibodies), livers were fixed with 4% formal-
dehyde and embedded in paraffin. Sections were either stained with hematoxylin and eosin, or used for in situ DNA end labeling using the terminal
uridyl transferase nicked ends labeling (TUNEL) method. Normal liver tissue is seen in a, whereas hepatocytes with pyknotic and fragmented nuclei are
surrounded by red blood cells in b. In situ DNA end labeling confirms apoptotic cell death in d.
1211 Schneider et al.
ately processed by proteolytic cleavage and the soluble
form released into the circulation can exert its various ac-
tivities locally and systemically. On the other end of the
spectrum stands CD40L, whose physiological activities,
such as B cell help, completely depend on the membrane
form, and for which processing has not been reported (47).
Local cell to cell contact appears to be critical for T cell–
specific immunosurveillance and, indeed, FasL-mediated
killing of virus-infected or tumor target cells is a highly
specific process (4) that assures that neighboring cells or tis-
sues are not affected. This specificity can only be guaran-
teed if the cytotoxic ligand remains associated with the
lymphocytes. However, FasL is rapidly released from cells
and detectable levels of sFasL have been found in sera from
patients with large granular lymphocytic leukemias, NK
lymphomas (17), or melanoma (11). Considering the he-
patic toxicity of FasL, circulating sFasL, if active, would be
pathological. Neither patients with tumors nor individuals
with high numbers of activated T cells (for example, after a
viral infection) do suffer from hepatitis, implying that sFasL
in vivo is at best poorly active, in agreement with our re-
sults. We cannot exclude, however, that high local concen-
trations of sFasL, in conjunction with other cytotoxic
agents, may lead to cell death. 
Our experiments also suggest that the mere trimerization
of Fas by FasL may not suffice to transmit death signals. It is
thought that the trimeric FasL induces Fas trimer forma-
tion, followed by the binding of Fas-associated death do-
main–containing protein (FADD) to the death domain of
Fas (48–50). FADD then recruits the caspase FADD ho-
mologous IL-1b converting enzyme (ICE)-like protease
(FLICE)/MACH/caspase 8 (51, 52), providing the con-
nection of death receptors to caspases (53). The exact sto-
ichiometry of adapters mediating caspase activation has,
however, never been determined, and it is possible that
multiple Fas trimers are required to allow the assembly of
multiple FADD adapters bringing several FLICE proteins
together and allowing reciprocal cleavage and subsequent
activation of the caspase. The requirement of the formation
of large aggregates of Fas for signal transduction is also sug-
gested by the efficacy of agonistic antibodies of the IgM
and IgG3 type, which are known to be multimeric or to
form aggregates (54). 
It could be predicted from the results presented here that
circulating cells expressing membrane-bound FasL are
more potent inducers of systemic tissue damage, and that
the conversion of the ligand into the soluble form serves to
downregulate the potentially harmful apoptotic activity. If
true, the proposed use of metalloproteinase inhibitors to
treat systemic tissue damage caused by circulating sFasL
(17), which has proved efficient in the case of TNF-a (1,
2), could therefore result in an exacerbation rather than an
amelioration of the disease in the case of FasL. 
Figure 5. Trimeric sFasL binds to Fas receptor. (A) Interaction of Flag–
sFasL and Fas/Fc. Wells of microtiter plates were coated with fusion pro-
teins of Fas/Fc and incubated with either Flag-sFasL or anti-Flag–induced
cross-linked Flag–sFasL. After several washings, binding of the ligands was
determined by the addition of anti-Flag antibodies. (B) Binding of sFasL
to Fas on Jurkat T cells, A20 B cell lymphomas, and an A20 cell that has
lost Fas surface expression (A20R) was analyzed by flow cytometry using
tagged FasL or anti-muFas Jo-2 antibodies. The open curves were ob-
tained when the ligand or Jo-2 antibody was omitted.
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